Linvemastat not checked
Primevera Therapeutics, LLC. · FP-020
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
- Main trialPhase 2
- “This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, subjects receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 24 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if…”In the company’s words, NCT07191535 on ClinicalTrials.gov
- Other names
- FP-020
Other drugs for Asthma (Diagnosis)
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Coming up1
- 1 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 20 NovCompletion date moved: 2028-01-01 to 2028-03-01 · ClinicalTrials.gov NCT07191535
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Mar 2028 | Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026